Trials / Completed
CompletedNCT00224068
Effect of Iron Therapy as an Adjunct to Epoetin Alfa in the Anemia of Cancer Chemotherapy
A Multicenter, Randomized, Controlled Prospective Trial of the Safety and Efficacy of Ferrlecit® in Anemic Cancer Patients Who Are Receiving Acute Chemotherapy and Epoetin as Compared to Oral Iron and No Treatment
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 180 (planned)
- Sponsor
- Watson Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluates the safety and efficacy of Ferrlecit® (ferric gluconate; a form of intravenous iron) or ferrous sulfate (a form of oral iron) in improving the response to epoetin alfa among anemic cancer patients receiving chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sodium ferric gluconate, ferrous sulfate, standard of care |
Timeline
- Start date
- 2002-05-01
- Primary completion
- 2003-12-01
- Completion
- 2003-12-01
- First posted
- 2005-09-22
- Last updated
- 2012-03-02
Locations
32 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00224068. Inclusion in this directory is not an endorsement.